Teachers Retirement System of The State of Kentucky lifted its position in shares of G1 Therapeutics Inc (NASDAQ:GTHX) by 12.0% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 14,021 shares of the company’s stock after buying an additional 1,501 shares during the period. Teachers Retirement System of The State of Kentucky’s holdings in G1 Therapeutics were worth $733,000 at the end of the most recent quarter.
Several other hedge funds have also recently bought and sold shares of GTHX. Great West Life Assurance Co. Can boosted its position in G1 Therapeutics by 148.3% during the second quarter. Great West Life Assurance Co. Can now owns 2,612 shares of the company’s stock valued at $113,000 after purchasing an additional 1,560 shares during the last quarter. Strs Ohio boosted its position in G1 Therapeutics by 78.3% during the second quarter. Strs Ohio now owns 4,100 shares of the company’s stock valued at $178,000 after purchasing an additional 1,800 shares during the last quarter. WINTON GROUP Ltd acquired a new position in G1 Therapeutics during the third quarter valued at approximately $218,000. Metropolitan Life Insurance Co. NY boosted its position in G1 Therapeutics by 48.4% during the second quarter. Metropolitan Life Insurance Co. NY now owns 6,818 shares of the company’s stock valued at $296,000 after purchasing an additional 2,224 shares during the last quarter. Finally, State Board of Administration of Florida Retirement System acquired a new position in G1 Therapeutics during the second quarter valued at approximately $317,000. 71.02% of the stock is owned by institutional investors.
In other news, SVP Terry L. Murdock sold 3,519 shares of the firm’s stock in a transaction that occurred on Wednesday, October 3rd. The stock was sold at an average price of $49.18, for a total value of $173,064.42. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Seth Rudnick sold 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, October 4th. The shares were sold at an average price of $49.72, for a total value of $497,200.00. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 59,613 shares of company stock valued at $2,631,874. Insiders own 15.92% of the company’s stock.
Several research analysts recently commented on GTHX shares. BidaskClub cut G1 Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, September 19th. Needham & Company LLC increased their price target on G1 Therapeutics to $76.00 and gave the company a “buy” rating in a research report on Tuesday, September 18th. HC Wainwright reissued a “buy” rating and set a $79.00 price target on shares of G1 Therapeutics in a research report on Monday, September 17th. BTIG Research started coverage on G1 Therapeutics in a research report on Monday, September 10th. They set a “buy” rating and a $80.00 price target for the company. Finally, Cowen reissued a “buy” rating on shares of G1 Therapeutics in a research report on Thursday, August 9th. Two analysts have rated the stock with a hold rating and six have given a buy rating to the company. G1 Therapeutics presently has an average rating of “Buy” and an average price target of $74.00.
GTHX opened at $34.49 on Wednesday. G1 Therapeutics Inc has a 12-month low of $18.03 and a 12-month high of $69.57. The company has a market capitalization of $1.42 billion, a PE ratio of -9.66 and a beta of 1.07.
G1 Therapeutics (NASDAQ:GTHX) last released its quarterly earnings data on Wednesday, November 7th. The company reported ($0.59) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.67) by $0.08. Sell-side analysts anticipate that G1 Therapeutics Inc will post -2.49 EPS for the current year.
ILLEGAL ACTIVITY NOTICE: This piece of content was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of U.S. and international trademark and copyright laws. The legal version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/12/05/teachers-retirement-system-of-the-state-of-kentucky-purchases-1501-shares-of-g1-therapeutics-inc-gthx.html.
About G1 Therapeutics
G1 Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel small molecule therapeutics for the treatment of patients with cancer in the United States. It is developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase 1b/2a clinical trials for patients with small cell lung cancer, as well as Phase 2 clinical trial for patients with first-/second-/third-line metastatic triple-negative breast cancer; G1T38, an oral CDK4/6 inhibitor that is Phase 1b/2a clinical trials for the treatment of breast cancer; and G1T48, an oral selective estrogen receptor degrader, which is in preclinical development.
Further Reading: How Buying a Call Option Works
Receive News & Ratings for G1 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.